Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18 ILa | +4.65% | +11.80% | -52.88% |
Sales 2024 * | 17.57M 6.51B | Sales 2025 * | 29.87M 11.07B | Capitalization | 58.24M 21.59B |
---|---|---|---|---|---|
Net income 2024 * | -35M -12.98B | Net income 2025 * | -16M -5.93B | EV / Sales 2024 * | 3.31 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 * |
-2.43
x | P/E ratio 2025 * |
-
| Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
Latest transcript on BioLineRx Ltd.
1 day | +4.65% | ||
1 week | +11.80% | ||
1 month | +0.56% | ||
3 months | -43.57% | ||
6 months | -50.95% | ||
Current year | -52.88% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 09-05-23 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Aharon Schwartz
CHM | Chairman | 80 | 03-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-30 | 18 | +4.65% | 901,711 |
24-05-29 | 17.2 | -2.82% | 508,176 |
24-05-28 | 17.7 | +2.91% | 4,672,314 |
24-05-27 | 17.2 | -0.58% | 605,743 |
24-05-26 | 17.3 | +7.45% | 1,238,299 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 30, 2024 at 10:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.88% | 58.12M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- BLRX Stock